Advertisement: Wild Knight Vodka
Advertisement: CJBS mid banner
Advertisement: Birketts mid banner
Mid banner advertisement: BDO
ARM Innovation Hub
Barr Ellison Solicitors – commercial property
Advertisement: Mogrify mid banner
Advertisement: partnersand mid banner
Advertisement: Cambridge Network mid banner
Advertisement: HCR Hewitsons mid banner
Advertisement: Simpsons Creative mid banner
Advertisement: Bar Ellison mid banner property
Advertisement: TTP
Cambridgeand mid banner advertisement
Advertisement: SATAVIA mid banner
Advertisement: RSM mid banner
Advertisement: S-Tech mid banner 3
Advertisement: Kao Data Centre mid banner
4 August, 2022 - 09:58 By Tony Quested

All systems GO as Congenica targets cancer via US alliance

Cambridge-based digital health company Congenica has expanded its reach into the field of cancer through an alliance with US company GenomOncology (GO).

The companies have announced the collaborative development of a ground-breaking CE-IVD precision oncology solution.

Congenica’s capability enables the rapid analysis and interpretation of genomic data. It has recognised the increasing adoption of cancer genomics and the growing need to individualise therapeutic recommendations. 

That awareness is driving Congenica to start developing a fully automated data analysis application aimed at transforming the usability and scalability of genomic data for routine oncology clinical practice.

To further enrich decision support capabilities for this novel precision oncology solution, Congenica is collaborating with Ohio-based GenomOncology to provide regional therapy recommendations.

GO’s platform is designed to harmonise the latest precision oncology information, which includes an extensive set of annotations and ontologies as well as curated public, licensed, and proprietary content and data sets. 

By incorporating this comprehensive knowledge base, Congenica says it will have improved access to curated precision oncology information from the US, UK, EU and other territories to yield data-driven insights and recommendations.

Alistair Johnson, Chief Professional Services Officer at Congenica, said: “This collaboration signifies the expansion of Congenica’s Clinical Decision Support (CDS) Platform into oncology. 

“Our novel product offers a fully automated future-proof end-to-end solution that unlocks the full potential of Next Generation Sequencing in the clinical oncology space. 

“GenomOncology brings extensive experience in precision oncology care and its platform has been developed specifically to deliver clinical informatics solutions for cancer. We look forward to working with GenomOncology to further drive precision medicine, delivering high quality patient care and shaping the future of human health.”

Brad Werts, GO’s chief executive adds: “Our partnership with Congenica enables us to expand opportunities for precision oncology care at the global level. 

“The extensive information available within the GenomOncology Precision Oncology Platform, combined with the capabilities of the Congenica Clinical Decision Support Platform, will give clinicians and researchers the knowledge needed to provide their patients with the most appropriate care opportunities.” 

Based on pioneering research from the Wellcome Sanger Institute and the NHS, Congenica has a global footprint supporting leading international laboratories, academic medical centres and biopharmaceutical companies and is the exclusive Clinical Decision Support partner for the NHS Genomic Medicine Service.

Newsletter Subscription

Stay informed of the latest news and features